2020 Volume 20 Issue 2 Pages 71-76
Liposome is one of the fascinating drug delivery carrier. Several liposome formulations have been approved for clinical use. Most of the anticancer drugs, including the liposome formulations, need to be passed through the screening steps, which catch up the candidates with the highest antitumor effect, and then undergoing to the preclinical and clinical phases. However, the development process is slowed or even sometime prevented by the loss of understanding of pharmacokinetics of encapsulated drugs, the tumor immune modulation by liposome formulation, and the adverse reactions via induction of the specific antibodies to DDS carriers. In this article, we overview these issues we should pay further attention to develop liposomal formulation of anticancer drugs.
